Research progress of prostate health index in the diagnosis and treatment of prostate cancer
10.3760/cma.j.cn112330-20220401-00157-1
- VernacularTitle:前列腺健康指数在前列腺癌诊疗中的研究进展
- Author:
Zhiyong TAN
1
;
Shi FU
;
Jieming ZUO
;
Haifeng WANG
;
Jiansong WANG
Author Information
1. 昆明医科大学第二附属医院泌尿外科，昆明 650101
- Keywords:
Prostatic neoplasms;
Carcinoma;
Prostate health index;
Prostate-specific antigen;
Diagnosis;
Treatment
- From:
Chinese Journal of Urology
2023;44(3):234-236
- CountryChina
- Language:Chinese
-
Abstract:
Despite the increasing number of patients was diagnosed with prostate cancer due to widespread cancer screening, PSA testing does not differentiate between lethal and slow-growing inert prostate cancers. This leads to a proportion of patients being over-diagnosed and consequently over-treated.The current study has found that PSA exists as a precursor to post-translational modification, and that [-2]proPSA originates only from the peripheral zone of the prostate. Furthermore, the study has shown that prostate health index (PHI) calculated from [-2]proPSA, fPSA, and PSA has a higher positive predictive value for prostate cancer, making it useful in the diagnosis of clinically significant prostate cancer. This article reviews the progress of research related to PHI in prostate cancer diagnosis and treatment.
